NEW YORK, Dec. 30 (GenomeWeb News) - Genome Therapeutics and Genesoft Pharmaceuticals today announced that the US Securities and Exchange Commission has approved a registration statement related to their proposed merger that includes a proxy statement that will be mailed to shareholders of both companies.
In addition, the companies said they will each hold a special meeting of their stockholders to vote on the proposed merger and other related matters on Feb. 2, 2004.
The all-stock transaction, originally announced in November, is expected to close in the first quarter of 2004, subject to various closing conditions, including the approval by both companies' shareholders.